Navigation Links
FDA Approves Cervical Cancer Vaccine That Covers More HPV Strains
Date:12/11/2014

WEDNESDAY, Dec. 10, 2014 (HealthDay News) -- The U.S. Food and Drug Administration on Wednesday approved a new vaccine with expanded protection against the human papillomavirus (HPV), by far the leading cause of cervical and certain other cancers.

The agency said that Gardasil 9 can shield users against nine strains of the virus, compared to the four strains covered by Gardasil, the Merck & Co. vaccine approved in 2006. Merck also makes Gardasil 9.

"Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers," the FDA said in an agency news release.

"Vaccination is a critical public health measure for lowering the risk of most cervical, genital and anal cancers caused by HPV," Dr. Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research, said in the release. "The approval of Gardasil 9 provides broader protection against HPV-related cancers."

The U.S. Centers for Disease Control and Prevention currently recommends the HPV vaccine for boys and girls at age 11 or 12, so they are protected before being exposed to the sexually transmitted virus. One other HPV vaccine, Cervarix, was also approved by the FDA in 2009. Cervarix is made by GlaxoSmithKline and protects against two HPV strains strongly linked to cancer, HPV 16 and 18.

According to the FDA, the approval of Gardasil 9 was based on a clinical trial involving more than 14,000 girls and women aged 16 to 26 who were not infected with HPV at the start of the trial. Participants were given either Gardasil or Gardasil 9.

"Gardasil 9 was determined to be 97 percent effective in preventing cervical, vulvar and vaginal cancers caused by the five additional HPV types [31, 33, 45, 52, and 58]," the FDA said. "In addition, Gardasil 9 is as effective as Gardasil for the prevention of diseases caused by the four shared HPV types (6, 11, 16 and 18)."

For younger people -- boys and girls aged 9 through 15 -- Garadsil 9 was determined to be effective from measurements of immune-system antibody responses to the vaccine, the FDA explained. "Based on these results, the vaccine is expected to have similar effectiveness when used in this younger age group," the agency said.

In terms of safety, the FDA said that the most common adverse effects were injection site pain, swelling, redness and headaches.

Like Gardasil, Gardasil 9 is administered as three separate shots, with the second and third doses given two and six months after the first one, respectively.

This year, about 12,360 new cases of invasive cervical cancer will be diagnosed, and about 4,020 women will die from the disease, according to the American Cancer Society.

More information

Find out more about HPV at the U.S Centers for Disease Control and Prevention.

SOURCE: U.S. Food and Drug Administration, news release, Dec. 10, 2014

--


'/>"/>
Copyright©2014 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Approves Abuse-Resistant Narcotic Painkiller
2. FDA Approves New Vaccine to Protect Against Meningitis
3. FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes
4. FDA Approves New Obesity Drug
5. FDA Approves Cochlear Nucleus Hybrid Implant System with Input from Participants at Saint Luke's Midwest Ear Institute
6. FDA Approves New Drug to Combat Melanoma
7. Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed
8. California Highway Patrol Approves ADOMANI All-Electric School Bus
9. FDA Approves New Kind of Insomnia Drug
10. FDA Approves Highly Accurate At-Home Colon Cancer Test
11. FDA Approves New Type 2 Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves Cervical Cancer Vaccine That Covers More HPV Strains
(Date:9/19/2017)... Raton (PRWEB) , ... September 19, 2017 , ... ... the El Naturalista brand, developed by ACPG Laboratories, is coming soon to RonnieColemanNutrition.com. ... in Spain, and El Naturalista is a trusted, well-respected brand reliant on the ...
(Date:9/19/2017)... ... ... For decades doctors, nurses, and other healthcare providers have been trained to ... calculating their cardiovascular disease (CVD) risk in the next 10 years. , Imagine ... an estimated 10-year risk prediction! , Imagine if the weatherman says there is a ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... with the Davidson Fellows Scholarship on September 27 at a reception in Washington ... Technology, Engineering, Mathematics, Literature and Music. , “I am honored to be a ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency nursing expertise, skill ... Emergency Nurse (CEN®) certification according to a large-scale study announced today by ... conducted by the Human Resources Research Organization (HumRRO) in late 2016 and early ...
(Date:9/18/2017)... Bangkok, Thailand (PRWEB) , ... September 19, 2017 ... ... in Asia Pacific’s protein ingredient market , expected to grow at the ... Frost & Sullivan sharing the ‘Global Food Protein Trends & Growth Opportunities in ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Sept. 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting ... Rodman & Renshaw 19 th Annual Global Investment ... (12:25 p.m. Pacific time). The conference is being held at ...
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
Breaking Medicine Technology: